AR038700A1 - Anticuerpos monoclonales anti-tenascina humana - Google Patents

Anticuerpos monoclonales anti-tenascina humana

Info

Publication number
AR038700A1
AR038700A1 ARP030100622A ARP030100622A AR038700A1 AR 038700 A1 AR038700 A1 AR 038700A1 AR P030100622 A ARP030100622 A AR P030100622A AR P030100622 A ARP030100622 A AR P030100622A AR 038700 A1 AR038700 A1 AR 038700A1
Authority
AR
Argentina
Prior art keywords
human anti
tenascin
seq
monoclonal antibody
tenascine
Prior art date
Application number
ARP030100622A
Other languages
English (en)
Inventor
Santis Rita De
Anna Maria Anastasi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of AR038700A1 publication Critical patent/AR038700A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un nuevo anticuerpo monoclonal ST2146 anti-tenascina humana que tiene alta afinidad con respecto al antígeno nativo y alta selectividad tumoral. El hibridoma cST2146 produce en forma estable el anticuerpo en condiciones de cultivo de alta densidad y es adecuado para el desarrollo industrial de productos basados en ST2146. El ST2146 presenta propiedades que se pueden explotar para aplicaciones terapéuticas y de diagnóstico. Reivindicación (1): Anticuerpo monoclonal anti-tenascina humana cuyas secuencias de regiones variables de cadena liviana y pesada son SEQ ID NO: 1 y SEQ ID NO: 2, respectivamente, y los fragmentos proteolíticos del mismo se ligan a un epitopo antigénico dentro de la repetición tipo EGF de la tenascina humana C.
ARP030100622A 2002-02-26 2003-02-26 Anticuerpos monoclonales anti-tenascina humana AR038700A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35929902P 2002-02-26 2002-02-26

Publications (1)

Publication Number Publication Date
AR038700A1 true AR038700A1 (es) 2005-01-26

Family

ID=27766061

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100622A AR038700A1 (es) 2002-02-26 2003-02-26 Anticuerpos monoclonales anti-tenascina humana

Country Status (20)

Country Link
US (3) US7438908B2 (es)
EP (1) EP1478667B1 (es)
JP (1) JP4488746B2 (es)
KR (1) KR101048894B1 (es)
CN (1) CN1317303C (es)
AR (1) AR038700A1 (es)
AT (1) ATE480564T1 (es)
AU (1) AU2003215900B2 (es)
BR (1) BR0307994A (es)
CA (1) CA2475395C (es)
CY (1) CY1111108T1 (es)
DE (1) DE60334076D1 (es)
DK (1) DK1478667T3 (es)
ES (1) ES2352180T3 (es)
HK (1) HK1078589A1 (es)
MX (1) MXPA04008216A (es)
PL (1) PL213216B1 (es)
PT (1) PT1478667E (es)
SI (1) SI1478667T1 (es)
WO (1) WO2003072608A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040105A1 (it) * 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
EP2420252A1 (en) * 2006-08-04 2012-02-22 Novartis AG EPHB3-specific antibody and uses thereof
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
FR2930036B1 (fr) * 2008-04-11 2010-05-07 Assist Publ Hopitaux De Paris Procede de diagnostic d'une hypertension arterielle pulmonaire.
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
SG177252A1 (en) 2008-12-01 2012-03-29 Lab Corp America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
SG172983A1 (en) * 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
SG172984A1 (en) * 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-2 expression
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
WO2012051498A2 (en) * 2010-10-15 2012-04-19 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
US8813227B2 (en) 2011-03-29 2014-08-19 Mcafee, Inc. System and method for below-operating system regulation and control of self-modifying code
US9262246B2 (en) 2011-03-31 2016-02-16 Mcafee, Inc. System and method for securing memory and storage of an electronic device with a below-operating system security agent
US9032525B2 (en) 2011-03-29 2015-05-12 Mcafee, Inc. System and method for below-operating system trapping of driver filter attachment
US8863283B2 (en) 2011-03-31 2014-10-14 Mcafee, Inc. System and method for securing access to system calls
US8925089B2 (en) 2011-03-29 2014-12-30 Mcafee, Inc. System and method for below-operating system modification of malicious code on an electronic device
US9317690B2 (en) 2011-03-28 2016-04-19 Mcafee, Inc. System and method for firmware based anti-malware security
US8966629B2 (en) 2011-03-31 2015-02-24 Mcafee, Inc. System and method for below-operating system trapping of driver loading and unloading
US8959638B2 (en) 2011-03-29 2015-02-17 Mcafee, Inc. System and method for below-operating system trapping and securing of interdriver communication
US8966624B2 (en) 2011-03-31 2015-02-24 Mcafee, Inc. System and method for securing an input/output path of an application against malware with a below-operating system security agent
US9087199B2 (en) 2011-03-31 2015-07-21 Mcafee, Inc. System and method for providing a secured operating system execution environment
US9038176B2 (en) 2011-03-31 2015-05-19 Mcafee, Inc. System and method for below-operating system trapping and securing loading of code into memory
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
EP2791686B1 (en) * 2011-12-12 2017-02-15 Oxford University Innovation Limited Tenascin-c and use thereof in rheumatoid arthritis
JP6463331B2 (ja) 2013-03-15 2019-01-30 イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー 抗ヘプシジン抗体およびその使用
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
GB201602413D0 (en) * 2016-02-10 2016-03-23 Nascient Ltd Method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687732A (en) * 1983-06-10 1987-08-18 Yale University Visualization polymers and their application to diagnostic medicine
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994021293A1 (en) * 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
JPH08510909A (ja) * 1993-05-28 1996-11-19 ザ スクリップス リサーチ インスティチュート Ｃｄ１４媒介細胞活性化を抑制するための方法および組成物
US6335014B1 (en) * 1998-06-17 2002-01-01 The Institute Of Physical And Chemical Research Medicament for suppressing cancer metastasis
ITRM20020128A1 (it) 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Also Published As

Publication number Publication date
ATE480564T1 (de) 2010-09-15
EP1478667A1 (en) 2004-11-24
CN1639192A (zh) 2005-07-13
PL213216B1 (pl) 2013-01-31
KR101048894B1 (ko) 2011-07-13
AU2003215900B2 (en) 2008-09-25
EP1478667B1 (en) 2010-09-08
HK1078589A1 (en) 2006-03-17
ES2352180T3 (es) 2011-02-16
BR0307994A (pt) 2004-12-07
PL372803A1 (en) 2005-08-08
DK1478667T3 (da) 2010-12-20
CA2475395C (en) 2011-08-02
US20050106145A1 (en) 2005-05-19
CN1317303C (zh) 2007-05-23
PT1478667E (pt) 2010-12-09
CA2475395A1 (en) 2003-09-04
AU2003215900A1 (en) 2003-09-09
US20040005643A1 (en) 2004-01-08
JP4488746B2 (ja) 2010-06-23
SI1478667T1 (sl) 2010-12-31
US20110020219A1 (en) 2011-01-27
JP2005534615A (ja) 2005-11-17
US7438908B2 (en) 2008-10-21
WO2003072608A1 (en) 2003-09-04
US8048417B2 (en) 2011-11-01
DE60334076D1 (de) 2010-10-21
MXPA04008216A (es) 2004-11-26
KR20040086426A (ko) 2004-10-08
CY1111108T1 (el) 2015-06-11

Similar Documents

Publication Publication Date Title
AR038700A1 (es) Anticuerpos monoclonales anti-tenascina humana
PE20050727A1 (es) Anticuerpos dirigidos a c-met
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
ES2564252T3 (es) Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos
ES2653664T3 (es) Generación y caracterización de anticuerpos terapéuticos obtenidos mediante HuCal GOLD completamente humanos específicos de CD38 humano
HRP20090517T1 (en) Interleukin-10 antibodies
CO4480111A1 (es) Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes
RS54046B1 (en) ANTI-MIOSTATIN ANTITELA
HRP20160485T1 (hr) Anti-mezotelinska protutijela i njihova uporaba
CY1116913T1 (el) Τροποποιημενα κλασματα fab αντισωματων
CO6231040A2 (es) Moleculas y metodos para modular la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
ATE263189T1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
RS53743B1 (en) ANTI-GM-CSF ANTIBODIES AND THEIR USE
ES2621874T3 (es) Anticuerpos para MUC16 y métodos de uso de los mismos
ES2165851T3 (es) Proteinas multivalentes que se unen a antigenos.
RS52439B (en) HUMAN ANTIBODIES TO THE HUMAN DELTA SIMILAR LIGAND 4
PE20050712A1 (es) Anticuerpos rg1
PE20071055A1 (es) Anticuerpos anti mn
DE69932812D1 (de) Epitope in der viralen hüllproteine und spezifische antikörper gegen diese epitope: verwendung für die detektion von hcv viralantigene im empfängergewebe
PE20220708A1 (es) Anticuerpos anti-cd73
ATE166882T1 (de) Monoklonale antikörper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee